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Abstract
Germline mutations of the BRCA1 tumor suppressor gene are a major cause of familial breast and ovarian cancer.
BRCA1 plays critical roles in the DNA damage response that regulates activities of multiple repair and checkpoint
pathways for maintaining genome stability. The BRCT domains of BRCA1 constitute a phospho-peptide binding
domain recognizing a phospho-SPxF motif (S, serine; P, proline; × varies; F, phenylalanine). The BRCT domains are
frequently targeted by clinically important mutations and most of these mutations disrupt the binding surface of
the BRCT domains to phosphorylated peptides. The BRCT domain and its capability to bind phosphorylated protein
is required for the tumor suppressor function of BRCA1. Through its BRCT phospho-binding ability BRCA1 forms at
least three mutually exclusive complexes by binding to phosphorylated proteins Abraxas, Bach1 and CTIP. The A, B
and C complexes, at lease partially undertake BRCA1’s role in mechanisms of cell cycle checkpoint and DNA repair
that maintain genome stability, thus may play important roles in BRCA1’s tumor suppressor function.
Germline mutations of the BRCA1 tumor suppressor
gene are a major cause of familial breast and ovarian
cancer [1,2]. BRCA1 plays critical roles in a number of
diverse cellular processes that ensure genome integrity
and the increase risk of breast and ovarian cancer
caused by mutation of BRCA1 has been attributed to
increased genomic instability. To safeguard genome,
cells have evolved a defensive mechanism, called the
DNA damage response (DDR), to coordinate multiple
cellular responses including DNA repair, cell cycle
checkpoint regulation, transcription, senescence or
apoptosis etc., to counteract genotoxic stress [3-6].
BRCA1 appears to act as a central mediator of the cellu-
lar response to DNA damage that regulates the activities
of multiple repair and checkpoint pathways [3,5,7-10].
BRCA1 is a substrate of the central DNA damage
response kinases ATM/ATR that control the DDR. It is
required for homology directed repair, a pathway that
facilitates error-free repair of double-strand breaks
(DSBs) and resolution of stalled DNA replication forks
through homologous recombination (HR) [9-11] as well
as postreplicative repair in response to UV damage [12].
Recently it is suggested that much of BRCA1’sr o l ei n
maintaining genome stability is accounted for by its role
in maintaining heterochromatin integrity via H2A ubi-
quitination [13].
BRCA1 associates with multiple repair proteins and
cell cycle regulators and such a capability to form multi-
ple protein complexes contributes to its role in main-
taining chromosome stability and tumor suppression
(Figure 1). BRCA1 is a large protein of 1,863 amino
acids. It contains two important domains at each end of
the protein, a RING domain at the N-terminus and two
BRCT domains at the C-terminus. Many clinically
important mutations of BRCA1 gene frequently target
these two domains. BRCA1 dimerizes with BARD1
through the RING domain present on each or the pro-
tein, forming an ubiquitin E3 ligase [14,15]. Earlier stu-
dies suggested that the E3 ligase activity of BRCA1 is
essential for the DDR and tumor suppression function
of BRCA1 [16-19]. Although a recent study using mouse
embryonic stem cells and knock-in mouse models sug-
gested that the E3 ligase activity of BRCA1 is not
required for homology-directed repair of DSBs and
tumor suppression [20,21], the exact role of BRCA1 E3
ligase activity in DNA damage induced ubiquitin signal-
ing and tumor suppression remains obscure. Another
study examining mice carrying a pathogenic missense
mutant of BRCA1 (C61G), which not only inactivates
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although compromised tumor suppression function of
BRCA1, affects response to therapy possibly through
residual activity of this mutant in DNA repair [22]. On
the basis of in vitro assays, a number of ubiquitination
substrates have been proposed for BRCA1/BARD1 E3
ligase, including histones, g-tubulin, CTIP and BRCA1
itself, however, very few have been reported as sub-
strates in vivo [23-25]. It has also been suggested that
BRCA1/BARD1 is capable of interacting with various
E2s directing either mono-ubiquitination, or polyubiqui-
tination with different linkages, such as lysine 63 (K63)-,
lysine 48 (K48)- or lysine 6 (K6)- linkages [26,27]. A
recent study suggested that the BRCA1 mediated his-
tone ubiquitination is required for its role in suppressing
satellite DNA repeats transcription in the heterchroma-
tin region and maintenance of genome stability [13].
However it is still not clear whether BRCA1’sr o l ei n
maintaining histone H2A ubiquitination at heterochro-
matin satellite DNA repeats is important for
tumorigenesis.
BRCA1 forms three different complexes through
its C-terminus BRCT domains
The BRCT domains of BRCA1 constitute a phospho-
peptide binding domain recognizing a phospho-SPxF
motif (S, serine; P, proline; × varies; F, phenylalanine)
[28-30]. The fact that the BRCT domains are frequently
targeted by many clinically important mutations and
most of these mutations disrupt the binding surface of
the BRCT domains to phosphorylated peptides indicates
that they are integral for BRCA1’s tumor suppressor
function [31]. A recent study of mice carrying a BRCT
mutant of BRCA1 that is defective in recognition of
phosphorylated proteins and mice carrying an E3 ligase
defective mutant of BRCA1 indicates that BRCT phos-
phoprotein recognition but not the E3 ligase activity is
required for BRCA1 tumor suppression [20,21].
Although multiple proteins have been suggested to
associate with the C-terminus of BRCA1 protein, so far,
three proteins Abraxas (also known as Abra1, CCDC98),
Bach1 (also known as Brip1, FancJ) and CtIP (also
known as RBBP8) have been shown directly interact
with the BRCT domains of BRCA1 through the phos-
pho-SPxF motif in a phosphorylation-dependent manner
forming mutually exclusive complexes, which were thus
named as the A, B and C complexes of BRCA1
[29,32,33] (Figure 2). Although it remains largely
unknown how these complexes transmit BRCA1 signal-
ing, it appears that these three complexes of BRCA1 are
involved in multiple functions of BRCA1 and thus may
be essential for BRCA1’s tumor suppressor function.
This review will thus focus on a summary of the forma-
tion and functions of these three BRCA1-BRCT asso-
ciated complexes.
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Figure 1 BRCA1 domains and interacting proteins. BRCA1
contains a RING domain at its N-terminus, two BRCT domains at the
C-terminus and a coiled-coil domain upstream of BRCT domains.
The interacting proteins are shown under the region of BRCA1
required for their association. BRCA1 forms an E3 ligase with BARD1
through its RING domain dimerizing with a RING domain containing
protein BARD1. A ubiquitin hydrolase BAP1 also interacts with this
region. The C-terminal BRCT domains form a phospho-binding
module recognizing a phospho-SPxF motif. Abraxas, Bach1 and CtIP
have been shown directly bind to BRCT domain through the
phospho-SPxF motif. PALB2 binds to the coiled-coil domain of
BRCA1 and bridges BRCA1-BRCA2 interaction. A number of other
proteins have also been indicated binding to the C-terminal region
of BRCA1 or the central region of BRCA1. BRCA1 contains a S/TQ
cluster that is phosphorylated by ATM/ATR at multiple sites. In
addition, BRCA1 is also a substrate of Chk2
Figure 2 Three proteins Abraxas, Bach1 and CtIP contain p-
SPxF motif that binds to the BRCT domains of BRCA1.
Schematic diagram showing protein domains of three BRCA1-BRCT
associated proteins. The phospho-Ser-Pro-X-Phe (p-SPxF) motif is
illustrated on each protein. In addition, Abraxas contains a MPN-
domain that binds to Ub and a coiled-coil domain that interacts
with BRCC36. Abraxas also contains a ATM/ATR phosphorylation site
(T368). Bach1 contains a helicase domain. CtIP contains a coiled-coil
domain at its N-terminus that is responsible for dimerization of the
protein. T847 of CtIP is phosphorylated by CDK and the
phosphorylation is required for its ability to promote DNA end
resection. CtIP is also phosphorylated by ATM/ATR at S644, S679
and S745. The 509-557 region of CTIP binds to DNA directly in vitro
and is required for recruitment to DSB in cells [34]
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complex
The BRCA1 A complex contains at least five different
components: Rap80, Abraxas, NBA1 (also known as
MERIT40), BRE (also known as BRCC45) and BRCC36
[32,35-41]. Abraxas interacts with the BRCT domains of
BRCA1 through a phospho-serine group (p-S406) at the
C-terminus of Abraxas, and mediates the interaction of
the A complex with BRCA1. In fact, Abraxas appears to
serve as a central organizing adaptor protein that not
only mediates the interaction of the A complex and
BRCA1 but also bridges the interaction of each member
of the BRCA1-A complex [32,35,42]. It is worth noting
that NBA1 and BRE interaction is critical for maintain-
ing the integrity of the BRCA1-A complex [43]. NBA1
interacts with BRE through a C-terminal conserved
PxxR (P, proline; × varies; R, arginine) motif of the
NBA1 protein and a C-terminal UEV domain of the
BRE protein. Knockdown of NBA1 or BRE leads to
decreased levels of components of the complex and
compromised BRCA1-A complex function [43].
Modification of proteins by the covalent attachment of
ubiquitin (Ub) to the lysine residue of a target protein is
a key regulatory mechanism of many cellular processes
including DNA damage response [44,45]. Ubiquitination
occurs through a three-step process involving Ub-acti-
vating enzyme (E1), Ub-conjugating (E2) and Ub-ligating
(E3) enzyme. The types of Ub modifications that can
form are diverse. Monoubiquitin occurs as a single Ub
molecule is attached. Alternatively, a polyubiquitin
(polyUb) chain is formed when one of the seven lysine
residues side chains within ubiquitin is linked to the C-
terminal glycine of another ubiquitin. The best-charac-
terized linkages to date utilize ubiquitin lysine 48 (K48)
and lysine 63 (K63). K48-linked polyUb predominantly
targets proteins for proteasomal degradation, whereas
K63-linked polyUb more often regulates protein func-
tion, subcellular localization, or protein-protein interac-
tions. K63 polyUb chain linkage plays important roles in
the recruitment of repair factors in the DDR [3].
Protein ubiquitination is a reversible process, and it
has become increasingly obvious that Ub deconjugation
plays important roles in regulating the Ub-dependent
pathways [46-49]. Deubiquitinating enzymes (DUBs) cat-
alyze the removal of Ub from Ub-conjugated substrate
proteins. DUBs also function in processing of Ub pre-
cursors and Ub adducts. BRCC36 in the BRCA1 A com-
plex is a deubiquitinating enzyme (DUB). BRCC36 was
initially identified as a BRCA1 associated protein that
contains a MPN
+/JAMM domain indicative of a metal-
loprotease activity [50]. It is later found indeed having a
deubiquitinating activity specifically toward K63-polyUb
linkages [38,51].
O n eu n i q u ef e a t u r eo ft h eB R C A 1Ac o m p l e xi st h a t
multiple ubiquitin binding motifs exist in the BRCA1 A
complex. Four members oft h eB R C A 1Ac o m p l e x ,
Rap80, Abra1, BRE, and BRCC36, possess polyUb chain
binding capability while only the UIM domains of
Rap80 display Lys63-linkage specific polyUb binding
[35]. BRCC36, Abraxas and BRE, which contains MPN
+,
MPN
- and UBC domain respectively, appear to prefer
b i n d i n gt ol o n g e rp o l y U bc h a i n sw i t hn oa p p a r e n tl i n k -
age specificity [35]. Thus, it is likely that the BRCA1 A
complex is assembled in a specific manner to facilitate
the DUB activity of BRCC36. Interestingly, the BRCA1
A complex bears similarities with the lid of the 19S pro-
teasome regulatory complex [35]. The 19S proteasome
lid [52,53] cleaves ubiquitin from substrates and facili-
tates the entry of substrates into the catalytic protea-
some core for degradation [54-56]. In the lid, Rpn11
contains an active MPN
+/JAMM motif that posesses a
DUB activity for substrate deubiquitination, while Rpn8
contains an enzymatically inactive MPN
- domain. Simi-
larly, the BRCA1 A complex contains a MPN
+/MPN
-
pair present in BRCC36 (MPN
+)a n dA b r a x a s( M P N
-)
proteins. These two proteins dimerizes with each other
through a coiled-coil domain on each of the protein. In
addition, while a component of the 19S proteasome lid,
Rpn10/S5a, contains UIM domains and a VWA domain
[57], in the BRCA1-A complex, Rap80 possesses UIM
domains at its N-terminus and NBA1 contains a VWA
domain. Although the significance of this similarity is
not clear, it is likely the BRCA1 A complex is assembled
to facilitate the cleavage of ubiquitin from substrates.
Indeed, it was shown that interactions of BRCC36 with
other components of the complex are critical for the
optimum DUB activity of BRCC36 [37,58]. In the
BRCA1 A complex, the UIM domains of Rap80 bind
specifically to K63-linked polyUb chains while the deu-
biquitinating enzyme BRCC36 displays an specificity
toward these chains [35,38,40,59]. Therefore, the BRCA1
A complex appears to be a DUB complex processing
K63-linked polyUb signals during the DDR.
BRCA1-A complex mediates DNA damage induced
ubiquitin signaling for recruitment of BRCA1 to
DSBs
Ubiquitination occurs at the double strand breaks
(DSBs) in a central DNA damage kinases ATM/ATR
dependent manner [3,4,6]. Upon DNA damage, a
damage induced ATM/ATR phosphorylation on Ser139
of histone H2AX directly recruits MDC1 through
MDC1’s BRCT domains. MDC1 itself is a substrate of
ATM/ATR, and its phosphorylation leads to the recruit-
ment of an ubiquitin E3 ligase/E2 conjugase, RNF8/
UBC13, to damage sites [42,60-62]. Another chromatin-
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fied working with Ubc13 to amplify the RNF8-depen-
dent polyubiquitin (polyUb) signal that is required for
BRCA1 recruitment [63,64]. The RNF8/RNF168 depen-
dent ubiquitination is further facilitated by yet another
E3 ligase HERC2 [65,66]. The subsequent ubiquitination
events on the damaged chromatin create docking sites
for DNA damage repair proteins such as 53BP1 and
BRCA1 [3,4,6]. In a parallel pathway, H2AX ubiquitaina-
tion by PRC1 also contributes to BRCA1 recruitment
[ 6 7 ] .S of a r ,h i s t o n e sH 2 Aa n dH 2 A Xh a v eb e e ni n d i -
cated as substrates of these E3 ligases although yet uni-
dentified substrates at DSBs may also likely exist. A
recent report indicates that MDC1 is likely to be
another substrate with a lysine residue in the MDC
BRCT domain ubiquitinated in a Ubc13-dependent
manner for interaction and optimum recruitment of
Rap80 [68]. Unlike the canonical Lys48-linked polyUb
that targets the substrate protein for proteasomal degra-
dation, RNF8/RNF168-dependent ubiquitination around
DNA damage sites appears to generate K63-linked
polyUb for recruitment of DNA repair proteins
[3,60-64].
The BRCA1 A complex accumulates to DSBs in a
RNF8/RNF168 dependent manner. The two UIM
domains of Rap80 and their capability to bind K63-
polyUb are required for accumulation of Rap80 and
other components of the BRCA1-A complex to sites of
damage [32,38,40,59]. The BRCA1 A complex plays an
important role in recruiting BRCA1 to DNA damage
sites. Down regulation of each component of this com-
plex compromised the recruitment of BRCA1 to DNA
damage sites, leading to increased cell sensitivity to ioniz-
ing radiation (IR) and inability of cells to arrest the cell
cycle as well as compromised homology recombination-
dependent repair in response to DNA damage
[32,35,36,38,40,69,70]. The exact role of the BRCA1-A
complex in DSB repair and BRCA1 signaling in tumor
suppression is still not clear. It is suggested that BRCC36
antagonizes RNF8-Ubc13 dependent ubiquitination such
that inhibition of BRCC36 leads to an increased accumu-
lation of RNF8/Ubc13-dependent ubiquitination at DSBs
[71]. In addition, it has been suggested that BRCC36 and
BRE might be involved in regulating the E3 ligase activity
of BRCA1/BARD1 [50]. Nevertheless, the fact that both
the BRCA1/BARD1 E3 ligase and the BRCC36 deubiqui-
tinating enzyme are present at DNA damage sites raises
the possibility that additional ubiquitin modifications
might be necessary to enhance or maintain the ubiquitin
signaling events initiated by the RNF8/RNF168 ligases.
Functional analyses of the BRCA1-A complex should
allow us to further dissect the role of BRCA1 in the DDR
and tumor suppression.
An independent DUB complex formed by Abraxas
paralog ABRO1
Abraxas protein has a paralog ABRO1 (Abraxas brother
1), which is 39% identical to Abraxas at the N-terminal
region including both a MPN
- domain and a coiled-coil
domain yet lacking the phospho-SPxF motif at its C-ter-
minus [32,37,43,58,72]. Interestingly, although ABRO1
does not interact with Abraxas, it assembles a DUB
complex in a similar manner as Abraxas with several
components of the BRCA1 A complex including
BRCC36, NBA1 and BRE. While Abraxas mainly loca-
lizes in the nucleus mediating the interaction of A com-
plex with BRCA1, ABRO1 is mainly localized in the
cytoplasm. Because it lacks the BRCA1 interacting
motif, ABRO1 does not interact with BRCA1. The
ABRO1 complex (also known as BRISC complex) con-
tains at least ABRO1, BRE, NBA1, and BRCC36.
ABRO1 and BRCC36 interaction is required for the
DUB activity of BRCC36 in vitro [72]. While Rap80
localizes in the nucleus and is only present in the
Abraxas/BRCA1-A complex, BRCC36, BRE, and NBA1
are expressed both in nucleus and cytoplasm and are
present in both complexes. The ABRO1/BRISC complex
appears to associate with the COP9 signalosome [51]. It
was also suggested that ABRO1/BRISC deficiency
enhances formation of the BRCA1-Rap80 interaction
and increased BRCA1 levels at the DNA damage sites
[37,58]. However, the exact role of the ABRO1/BRISC
complex needs further investigation to be understood.
BRCA1-A complex and Cancer
As c r e e no fn o n - BRCA1 or BRCA2 mutant familiar
breast tumors identified a in-frame deletion of residue
81 glutamic acid of Rap80 that displays reduced ubiqui-
tin binding and compromised ability to recruit A com-
plex and BRCA1 to DSBs [73]. Recently, two genome
wide association studies (GWAS) implicated that com-
mon genetic variants in NBA1 may predispose women
to serous ovarian or hormone negative breast cancer
[74,75]. In addition, BRCC36 gene is abnormally
expressed in several breast cancer cell lines and a subset
of sporadic breast tumors [50]. Together, it indicates
that BRCA1-A complex may play an important role in
breast tumor development.
BRCA1-B complex is required for replication stress
induced checkpoint control and DNA interstrand
crosslink repair
The BRCA1-B complex is formed through phosphory-
lated S990 of Bach1 binding to BRCA1 BRCT [29].
Bach1 Ser990 is phosphorylated by CDK in a cell cycle-
dependent manner [29,76]. Earlier, it was found that
Bach1 is required for progression through S phase [77]
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lates cells at G2 phase (G2 accumulation) after DNA
damage [29,76]. In fact, Bach1 interacts with TopBP1
forming a complex that is required for replication stress
induced checkpoint [78]. Both TopBP1 and Bach1 are
required for the extension of single stranded DNA
regions and RPA loading following replication stress
[78].
Bach1 was first identified as a DEAH helicase domain
containing protein that binds to the BRCT domains of
BRCA1 [79]. It was then discovered to be a member of
the Fanconi anemia protein, FancJ [80-83]. Fanconi ane-
mia (FA) is a rare genetic disorder associated with var-
ious developmental defects and a high incidence of
malignancies [84-86]. The FA patients’ cells are extre-
mely sensitive to agents that induce DNA interstrand
crosslinks [84-86] indicating that Bach1 plays a role in
the DNA interstrand crosslink repair.
In vitro studies suggest that Bach1 is a DNA depen-
dent ATPase, which unwinds DNA in a 5’ to 3’ direction
[87]. Furthermore, Bach1 preferentially binds and
unwinds DNA substrates that mimic an intermediate
step in homologous recombination [88]. Indeed, Bach1
is required for DNA repair through HR. Expression of a
helicase dead mutant of FancJ in cells results in the
accumulation of unrepaired DNA breaks and decreased
HR [79]. In addition, depletion of Bach1 by siRNAs was
also shown to compromise HR [82,86]. Bach1 enzyme
activity as well as the BRCA1-FancJ interaction is essen-
tial for DNA repair, checkpoint activation and tumor
suppression [29,89,90].
Multiple germline mutations that disrupt Bach1
enzyme activity or BRCA1 association have been identi-
fied in breast cancer indicating Bach1 is a tumor sup-
pressor [89]. Recently a frame shift mutations in the
Bach1 gene that greatly affect the risk of invasive ovar-
ian cancer has also been identified in ovarian cancer
[91].
BRCA1-C complex is required for DNA end
resection
The BRCA1-C complex consists of CtIP and the MRN
(Mre11/Rad50/Nbs1) complex. BRCA1 forms such a
complex with CtIP and MRN in a cell cycle-dependent
manner during S and G2 phase of the cell cycle
through the BRCT domains of BRCA1 binding to
phosphorylated S327, a CDK phosphorylation site of
CtIP in a phospho-SPxF motif [76,92]. CtIP is a func-
tional homolog of yeast Sae2 and is required for DNA
end resection at the initial step of homologous recom-
bination (HR) dependent DSB repair [93,94]. CtIP pro-
motes DNA end resection by interacting and
stimulating the nuclease activity of the MRN complex.
The complex formation of BRCA1-CtIP-MRN is
important for facilitating DSB resection to generate
single-stranded DNA that is needed for HR-mediated
DSB repair [92].
Similar to Sae2, of which CDK-dependent phosphor-
ylation promotes resection activity, CDK phosphoryla-
tion of CtIP at T847 is required for DSB resection and
subsequent HR in the S and G2 phase [95,96]. Recruit-
ment of CtIP to DSB requires MRN [34,92,97]. Both of
the N-terminus and C-terminus of CtIP have been
indicated to interact with the NBS1 subunit of the
MRN [92,94,97]. CtIP recruitment to damage sites also
requires ATM kinase activity [34]. It was shown that
S664/S745 phosphorylated by ATM is required for
CtIP recruitment to DNA damage sites and DSB end
resection [98]. It was also s u g g e s t e dt h a tf o l l o w i n g
DNA damage the ubiquitination of CtIP by BRCA1 is
critical for the recruitment of CtIP towards a chroma-
tin fraction [25]. In addition, like Sae2, CtIP is acety-
lated, and deacetylation of CtIP by SIRT6 promotes
DNA end resection [99,100].
CtIP is also implicated a role in microhomology-direc-
ted alternative nonhomolgous end-joing pathway (alt-
NHEJ) and the CtIP-mediated alt-NHEJ has a primary
role in chromosome translocation formation and class
switch recombination [101,102]. A study in chicken
DT40 cells analyzing a mutant of CTIP that fails to
associate with BRCA1 suggested that BRCA1-CtIP inter-
action is required for HR-mediated repair during S-G2
phase progression but involved in microhomology-
mediated NHEJ in a BRCA1-independent manner in G1
phase of the cell cycle [103]. Yet another study in
chicken DT40 cells suggested that CtIP interaction with
BRCA1 is not required for HR-mediated repair [104].
While the discrepancy needs to be further analyzed, the
biological significance of the complex formed between
BRCA1 and CtIP has not yet been fully studied in mam-
malian cells.
CtIP is an essential gene in mammalian cells, inactiva-
tion of which is embryonic lethal in mice [105]. How-
ever, haploid insufficiency of CtIP predisposes mice to
multiple types of tumor indicating CtIP is a tumor sup-
pressor [105]. Consistent with its role in the DDR, a
recent report showed that mutations of CtIP that gener-
ates a dominant-negative C-terminus truncated form of
CtIP protein causes Seckel and Jawad Syndromes which
is a genome instability disorder and associated with can-
cer predisposition [106].
Functions of BRCA1 A, B and C complexes in DNA
DSB repair
Eukaryotic cells possess at least three distinct mechan-
isms for DSB repair including NHEJ (non-homologous
end joining), SSA (single-strand annealing) and HR
(homologous recombination) [4,107]. NHEJ involves the
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error prone if terminal bases are removed prior to liga-
tion. SSA utilizes short stretches of sequence homology
flanking the break following DSB resection for annealing
resulting in deletion of intervening sequences and loss
of genetic information. In contrast to the error-prone
repair mechanisms NHEJ and SSA, HR accurately repair
DSBs in S-phase and G2-phase cells. HR is initiated by
nucleolytic processing of the DSB end to generate 3’
ssDNA (single-stranded DNA) overhangs. In the pre-
sence of ATP, Rad51 forms a helical nucleoprotein fila-
ment on ssDNA that is needed for invasion of the
ssDNA into a donor sister chromatid or homologous
chromosome to form a joint molecule for homologous
recombination. The BRCA1-C complex plays a critical
role in the initial resection of DSB end. This is followed
by long-range resection dependent on the DNA exonu-
clease Exo I and the helicase Bloom syndrome protein
(BLM), which provides the ssDNA substrates for HR
[107]. The BRCA1-B complex also plays a role in HR,
yet its specific mechanism remains unclear. BRCA1
associates with BRCA2 through PALB2 [108-110].
BRCA2 promotes the loading of Rad51 to ssDNA for
efficient HR repair [111]. Intriguingly it is still not clear
how the BRCA1-A complex is involved in HR. Although
an earlier report indicated BRCA1 A complex promotes
HR since HR is compromised in BRCA1-A complex
deficient cells [32], more recent reports suggest that
BRCA1-A complex supresses HR such that with deple-
tion of Rap80 or Abraxas, both the B and C complexes
assembly at DSB was increased and HR was hyperacti-
vated [112,113]. While it awaits further study for a bet-
ter understanding of how each of the complex
contribute to HR, it is clear that BRCA1 BRCT is critical
for HR at least partially through forming the A, B and C
complexes.
Functions of BRCA1 A, B and C complexes in DNA
damage induced checkpoint regulation
Studies on A, B and C complexes of BRCA1 indicate
that these complexes carry out functions of BRCA1 in
cell cycle checkpoint control. Both A and C complexes
of BRCA1 have been indicated critical for G2-M
checkpoint control in response to IR to ensure that
entry into mitosis is transiently inhibited to avoid aber-
rant chromosome segregation [32,35,36,38,40,69,70].
Interestingly knocking down any components of the A
complex such as Rap80, Abraxas, NBA1, BRE, BRCC36
or the C complex component CtIP, the phenotype of
G2-M checkpoint deficiency is much milder compared
to cells depleted of BRCA1 indicating that only partial
function of BRCA1 in G2-M checkpoint control is
defective when individualc o m p l e xw a sd e f i c i e n t
[32,35,36,38,40,69,70,76]. In fact, synthetic knockdown
of both Abraxas and CtIP proteins led to a G2-M
checkpoint defect comparable to BRCA1-deficient cells
[32] indicating that BRCA1 function in G2-M check-
point control might involve both of the A and C com-
plexes. While the B complex does not appear to be
involved in the transient G2-M checkpoint control
[76], it is required for G2-accumulation checkpoint
that is also observed for BRCA1-deficient cells
[29,76,114]. The mechanism of the G2-accumulation
checkpoint is still not well defined. In addition, the B
complex of BRCA1 is also involved in the replication
checkpoint control in response to replication stress
[78]. Since BRCA1 appears to be required for multiple
checkpoints regulation including the replication check-
point and G2-M checkpoint control, different BRCA1
associated complexes may only carry out partial of its
function in distinctive checkpoints.
Concluding remarks
The BRCT domain of BRCA1 has been indicated impor-
tant for cell cycle checkpoint, HR and tumor suppres-
sion [3,5,7-10]. The recent mouse model expressing a
BRCT mutant of BRCA1 (S1598F, corresponding to
human BRCA1 S1655F) incapable of binding to phos-
pho-peptides in place of the wild type allele of BRCA1
failed to suppress breast tumor development further
confirms that the BRCT domain and its capability to
bind phosphorylated protein is required for the tumor
suppressor function of BRCA1 [21]. Through its BRCT
phospho-binding ability BRCA1 forms at least three
mutually exclusive complexes by binding to phosphory-
lated proteins Abraxas, Bach1 and CTIP. The A, B and
C complexes, at lease partially undertake BRCA1’sr o l e
in mechanisms of cell cycle checkpoint and DNA repair
that maintain genome stability (Figure 3), although it
remains largely unknown how the formation of these
complexes are regulated or coordinated. Many other
proteins have also been reported binding to the BRCT
domains of BRCA1 although it is not clear whether
these proteins bind with a direct interaction [115,116].
It is likely additional BRCT associated complexes exist
carrying additional roles of BRCA1 in a number of
diverse cellular processes in maintaining genome stabi-
lity and tumor suppression.
Although it is evident that BRCT domains are essen-
tial for BRCA1’s tumor suppression, it remains unclear
how the BRCT domain associated complexes are coordi-
nated with signaling complexes that associate through
other regions of the BRCA1 protein. Together, BRCA1
emerges to be a central mediator of the cellular
Wang Cell & Bioscience 2012, 2:6
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Page 6 of 10mechanism that maintains genome stability that brings
together multiple signaling complexes in response to
DNA damage, yet much remains to be learned to fully
appreciate the role of BRCA1 as a tumor suppressor.
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